Clinical trials: Platelet Transfusion
- Condition Platelet Transfusion
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Thrombocytopenia
Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products
The primary objective of the study is to measure platelet corrected count increments and the incidence of serious adverse events (SAE).
- Trial name
- NCT00263809
- Testing
- Pathogen Reduction Technology
- Where
- 10 sites in France
- Volunteers
- 118 people
- Sponsor
- Terumo BCTbio
Transfusion Related Acute Lung Injury
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
This study is a prospective, non-randomized sequential cohort, open label, multi-center, non-inferiority, Phase IV surveillance study following transfusion of INTERCEPT PCs.
- Trial name
- PIPER (NCT02549222)
- Testing
- Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 2,291 people
- Sponsor
- Cerus Corporation
Chikungunya Virus, Dengue Virus
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions.
- Trial name
- TRUE (NCT02305732)
- Testing
- INTERCEPT Platelets
- Where
- 8 sites in Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Cerus Corporation